ClinicalTrials.gg
CompletedNCT02607904Updated Dec 20, 2022

An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

A Phase 2 interventional study of GWP42003-P in Epilepsy, sponsored by Jazz Pharmaceuticals. Completed at 5 sites in 3 countries. Open to participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
16 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing cannabidiol in Epilepsy — 2 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Epilepsy.

Enrollment
12th of 20
30 · median 35
Started
2016
with 3 others
Phase 2
6 of 20
none open now
Registered
10th of 20
by date
Lead sponsor
11 of 20
Jazz Pharmaceuticals

Among the 20 studies testing cannabidiol in Epilepsy, this one is the 12th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 2, and was the 10th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 20 studies testing cannabidiol in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing cannabidiol in Epilepsy, or all of them as a file.
02

Study summary

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Cannabidiol
  • GWP42003-P
  • Epidiolex
  • Stiripentol
  • Valproate
04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Note: Participants who enroll in France or Sweden must be aged 18-55 years.

Key Inclusion Criteria:

  • Participant must have a documented magnetic resonance imaging/computerized tomography of the brain that ruled out a progressive neurologic condition.

Key Exclusion Criteria:

  • Participant has unstable medical conditions other than epilepsy.
  • Participant has a history of symptoms related to a drop in blood pressure due to postural changes (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope).
  • Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month.
  • Participant is currently using felbamate and has been taking it for less than 12 months prior to screening visit of the blinded phase of the trial.
  • Participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to trial entry.
  • Participant has any known or suspected history of any drug abuse or addiction.
  • Participant is unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex) for the duration for the trial.
  • Participant has any known or suspected to cannabinoids or any of the of the Medicinal Product (IMP), e.g., sesame oil.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    GWP42003-P

    Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase). Participants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found. Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early.

    Drug: GWP42003-P

Interventions

  • Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

    Also known as: Cannabidiol, CBD, Epidiolex

06

What researchers measure

Primary outcomes

  1. Number of participants who experienced an adverse event.

    The number of participants who experienced an adverse event during the trial is presented.

    Time frame: Up to 48 weeks.

Secondary outcomes

  1. Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).

    The number of participants with a clinically significant change in ECG is presented.

    Time frame: Up to 48 weeks.

  2. Number of participants with a clinically significant change in serum biochemistry.

    The number of participants with a clinically significant change in serum biochemistry is presented.

    Time frame: Up to 48 weeks.

  3. Number of participants with a clinically significant change in hematology.

    The number of participants with a clinically significant change in hematology is presented.

    Time frame: Up to 48 weeks.

  4. Number of participants with a clinically significant change in urinalysis.

    The number of participants with a clinically significant change in urinalysis is presented.

    Time frame: Up to 48 weeks.

  5. Number of participants with a clinically significant change in vital signs.

    The number of participants with a clinically significant change in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) is presented.

    Time frame: Up to 48 weeks.

  6. Number of participants with a clinically significant change in physical examination.

    The number of participants with a clinically significant change in physical examination is presented.

    Time frame: Up to 48 weeks.

  7. Number of participants with a treatment-emergent suicidality flag.

    Suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The number of participants with a treatment-emergent flag is presented.

    Time frame: Up to 48 weeks.

  8. Seizure frequency by subtype.

    The frequency of each subtype of seizure at baseline and end of treatment is presented.

    Time frame: Up to 48 weeks.

  9. Number of participants with a treatment-emergent finding indicative of drug abuse liability.

    Abuse liability was assessed through monitoring of triggering adverse events of interest and study medication accountability discrepancies. Any findings were assigned to an appropriate classification by the investigator. The number of participants with a treatment-emergent finding indicative of drug abuse liability is presented.

    Time frame: Up to 48 weeks.

07

Study locations

5 sites
  • SEIN - Epilepsy Institute in the Netherlands Foundation
    Zwolle, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Ruber Internacional
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Sahlgrenska University Hospital
    Göteborg, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in May 2019, 29 months.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 29 months is above that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Nov 18, 2015
StartActual
Dec 15, 2016
Primary completionActual
May 27, 2019
CompletionActual
May 27, 2019
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02607904
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Dec 15, 2016
Primary completion
May 27, 2019
Completion
May 27, 2019
Last update
Dec 20, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion